Clinical Trials Logo

Fallopian Tube Carcinoma clinical trials

View clinical trials related to Fallopian Tube Carcinoma.

Filter by:

NCT ID: NCT01611766 Active, not recruiting - Clinical trials for Primary Peritoneal Carcinoma

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

Start date: July 19, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian cancer.

NCT ID: NCT01519869 Completed - Clinical trials for Primary Peritoneal Carcinoma

Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma

Start date: March 2012
Phase: Phase 2
Study type: Interventional

This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical cytoreduction rates, comparable survival, decreased morbidity, and increased quality of life in patients with International Federation of Gynecologic Oncology stages IIIC and IV ovarian, primary peritoneal, or fallopian tube cancer when compared to historical controls and to evaluate the hypothesis that cancer induced inflammation is a predictor of poor prognosis and response to therapy in this group of ovarian cancer patients.

NCT ID: NCT01445275 Not yet recruiting - Clinical trials for Primary Peritoneal Carcinoma

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

Start date: January 2100
Phase: N/A
Study type: Observational

This research trial collects information about types of treatment and the cost of these procedures in women with elevated genetic risk for ovarian cancer who participated on the Gynecology Oncology Group (GOG)-0199 trial. Gathering information about women at elevated genetic risk for ovarian cancer may help doctors learn more about risk reduction procedures and the cost of these procedures.

NCT ID: NCT01381861 Completed - Clinical trials for Primary Peritoneal Carcinoma

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Start date: July 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

NCT ID: NCT01295489 Completed - Clinical trials for Primary Peritoneal Carcinoma

Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Start date: March 2011
Phase:
Study type: Observational

This research trial studies biomarkers in patients with previously untreated invasive ovarian epithelial, fallopian tube, or primary peritoneal cancer. Studying samples of tumor tissue, peritoneal cavity fluid, and blood from patients receiving chemotherapy directly into the abdominal cavity (intraperitoneal) may help doctors learn more about the effects of intraperitoneal chemotherapy on cells. It may also help doctors identify and learn more about biomarkers related to cancer.

NCT ID: NCT01202890 Terminated - Ovarian Cancer Clinical Trials

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Start date: September 2010
Phase: Phase 1
Study type: Interventional

This study will test the feasibility of combining 3 drugs, Revlimid with Doxil and Bevacizumab,and gather preliminary data on the potential activity of the combination in patients with platinum resistant/refractory ovarian cancer.

NCT ID: NCT01139957 Completed - Breast Carcinoma Clinical Trials

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Start date: June 7, 2010
Phase:
Study type: Observational

This clinical trial is studying the incidence of cancer in women at increased genetic risk of ovarian cancer. Gathering information about genetic factors in women with an increased risk of ovarian cancer over time may help doctors learn more about the disease and find better methods of treatment and on-going care.

NCT ID: NCT01118052 Completed - Clinical trials for Recurrent Ovarian Carcinoma

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Start date: November 1, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well EGEN-001 works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that is persistent or has come back. Biological therapies, such as EGEN-001, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing.

NCT ID: NCT01116648 Active, not recruiting - Clinical trials for Triple-Negative Breast Carcinoma

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Start date: April 14, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well they work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement (recurrent). Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may be safe, tolerable and/or effective in treating patients with recurrent ovarian, fallopian tube, or peritoneal cancer or recurrent triple-negative breast cancer.

NCT ID: NCT01097746 Completed - Clinical trials for Primary Peritoneal Carcinoma

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Start date: April 14, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well first-line treatment of bevacizumab, carboplatin, and paclitaxel work in treating participants with stage III- IV ovarian, primary peritoneal and fallopian tube cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bevacizumab, carboplatin, and paclitaxel as first-line treatment may work better at treating ovarian, primary peritoneal, and fallopian tube cancer.